Roche's key products like Vabysmo, Ocrevus, and Phesgo are performing well. Read why RHHBY stock looks well positioned to ...

Sanofi has ended a Phase 2 clinical trial into oditrasertib, an investigational RIPK1 inhibitor therapy, in people with relapsing and progressive multiple sclerosis (MS) after it failed to meet ...

But three — tolebrutinib, fenebrutinib, and remibrutinib — are now in late-stage trials. The race is on as several drugmakers get closer to the finish line in developing the first Bruton tyrosine ...

A positive result for Bruton’s tyrosine kinase inhibitor after the drug had been put on partial clinical hold due to concerns about liver toxicity.

She also notes reassuring results from longer-term trials of fenebrutinib, another BTK inhibitor, in patients with relapsing MS. In all, as these therapies progress through trials, Dr Oh is ...